Claustrum serotonin and spike-timing plasticity associated with cognitive deficits after cocaine
Project Number5F31DA055445-02
Former Number1F31DA055445-01
Contact PI/Project LeaderANDERSON, TANNER
Awardee OrganizationUNIVERSITY OF KENTUCKY
Description
Abstract Text
Project Summary/Abstract
Over 40 million individuals in the US have a substance use disorder (SUD), and therapies for treating SUD have
remained largely inadequate for decades. One of the key challenges in SUD treatment is that many drugs of
abuse, including cocaine, negatively impact cognitive flexibility, leaving patients less likely to abstain from drug
use. An emerging body of literature shows that agonists of the serotonin 2A receptor (5HT2AR), psychedelic
hallucinogens, have remarkable potential for improving long-term cognitive flexibility with implications for treating
various psychiatric disorders, including substance use. The highest density of the 5HT2AR expression in the
brain is in the claustrum (CLA), an understudied subcortical brain structure with extensive innervation of fronto-
cortical areas. The main projection target of the CLA is the anterior cingulate cortex (ACC), and both the CLA
and the ACC have been implicated in regulation of drug-seeking behavior and cognitive flexibility. My preliminary
behavioral data in rats show that extended access to self-administered cocaine induces cognitive flexibility
deficits in a strategy set-shift task, and that 5HT2ARs in the CLA likewise robustly modulate set-shift task
performance. Preliminary electrophysiology data show that 5HT induces inhibition of glutamatergic
neurotransmission in CLA neurons projecting to the ACC (CLA-ACC neurons) by activating CLA 5HT2ARs.
Furthermore, serotonergic signaling via the 5HT2ARs has a profound impact on long-term plasticity of CLA
synapses. My preliminary data indicate that application of 5HT2AR agonist, DOI, reverses spike timing-
dependent long-term depression (t-LTD) in CLA-ACC neurons and promotes, instead, spike timing-dependent
long-term potentiation (t-LTP) of glutamatergic signaling in these cells. The current proposal will test the
hypothesis that cocaine changes the timing window for induction of long-term synaptic plasticity in CLA-ACC
neurons resulting in cognitive flexibility deficits and increased drug seeking behavior. I speculate that a single
activation of 5HT2ARs in the CLA reverses cocaine-induced LTD, with a long-term improvement of cognitive
flexibility leading to attenuated reinstatement of cocaine-seeking behavior. I will test this hypothesis by targeted
microinjections of DOI into the CLA of rats trained to self-administer cocaine. I will use patch-clamp
electrophysiology to establish the timing rules for serotonergic modulation of spike-timing dependent plasticity of
excitatory synapses onto CLA-ACC neurons of cocaine exposed rats. Finally, I will combine chemogenetics with
Ca2+ imaging in ACC-containing brain slices to establish the extent to which CLA neurons control ACC excitability
in control and cocaine experienced rats. The findings of this proposal will reveal the role of CLA serotonin as a
novel regional target for substance use research and specifically explore the impact of 5HT2ARs in the CLA on
cortically-mediated cognitive flexibility deficits linked to cocaine use.
Public Health Relevance Statement
Project Narrative
Drug-seeking and drug relapse behaviors are linked to deficits in cognitive flexibility that are induced by history
of substance use. We hypothesize that the anterior cingulate cortex, a key brain structure that regulates cognitive
flexibility, is under potent inhibitory control by the serotonin 2A receptors within the claustrum, a little-studied
subcortical brain area. Psychedelic serotonin 2A receptor agonists are under active investigation of therapeutic
potential for substance use disorder symptoms in humans, and our research proposes a central role for
serotonin-dependent plasticity at claustro-cortical synapses in development of drug-induced cognitive deficits in
a rat model of cocaine self-administration.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AgonistAnimalsAnteriorAreaAttenuatedBehaviorBehavioralBilateralBrainCellsCerebral DominanceClaustral structureCocaineCognitiveCognitive deficitsDataDrug RegulationsDrug usageElectrophysiology (science)Excitatory SynapseFunctional Magnetic Resonance ImagingGeneticGlutamatesGoalsHabitsHallucinogensHumanImageIndividualInsula of ReilInvestigationLinkLiteratureLong-Term DepressionLong-Term PotentiationMajor Depressive DisorderMediatingMediatorMental disordersMicroinjectionsModelingModificationNeuronsOutputPatientsPatternPharmaceutical PreparationsPicrotoxinProtocols documentationRattusRecording of previous eventsRegulationRelapseResearchRoleSalineScientistSerotoninSerotonin AgonistsSerotonin Receptor 5-HT2ASignal TransductionSliceStructureSubstance Use DisorderSubstance abuse problemSymptomsSynapsesSynaptic plasticityTask PerformancesTestingTherapeuticTrainingWithdrawalantagonistbehavioral phenotypingcareer developmentcingulate cortexcocaine exposurecocaine seekingcocaine self-administrationcocaine usedensitydrug developmentdrug of abusedrug relapsedrug seeking behaviorexperienceexperimental studyflexibilityglutamatergic signalingimprovedin vivoin vivo Modelnerve supplyneurotransmissionnovelpatch clampputamenreceptorsubstance usesubstance usersynaptic inhibition
No Sub Projects information available for 5F31DA055445-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5F31DA055445-02
Patents
No Patents information available for 5F31DA055445-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5F31DA055445-02
Clinical Studies
No Clinical Studies information available for 5F31DA055445-02
News and More
Related News Releases
No news release information available for 5F31DA055445-02
History
No Historical information available for 5F31DA055445-02
Similar Projects
No Similar Projects information available for 5F31DA055445-02